VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Jerome Galon on the Prognostic Value of Immunoscore

Jerome Galon, PhD
Published: Thursday, Jun 16, 2016

Jerome Galon, PhD, research director at Inserm and head of the Laboratory of Integrative Cancer Immunology, discusses the prognostic value of the Immunoscore®Colon assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.

Immunoscore® has been a project in development since 2005 to stratify patients into high- and low-risk categories. Results of an international validation study, which tested Immunoscore® in 3855 patients, demonstrated its prognostic value in patients with stage I, II, and III colon cancer.

Highlights of the ASCO presentation entitled “Validation of the Immunoscore® as a prognostic marker in stage I/II/III colon cancer” were that primary endpoint of the study has been reached, with significantly longer time to recurrence for patients classified as Immunoscore-High. Immunoscore® was also able to predict disease-free survival and overall survival among stage I, II, and III patients with colon cancer and importantly, in stage II patients, the Immunoscore® classification identified a subgroup of high-risk patients.
Jerome Galon, PhD, research director at Inserm and head of the Laboratory of Integrative Cancer Immunology, discusses the prognostic value of the Immunoscore®Colon assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.

Immunoscore® has been a project in development since 2005 to stratify patients into high- and low-risk categories. Results of an international validation study, which tested Immunoscore® in 3855 patients, demonstrated its prognostic value in patients with stage I, II, and III colon cancer.

Highlights of the ASCO presentation entitled “Validation of the Immunoscore® as a prognostic marker in stage I/II/III colon cancer” were that primary endpoint of the study has been reached, with significantly longer time to recurrence for patients classified as Immunoscore-High. Immunoscore® was also able to predict disease-free survival and overall survival among stage I, II, and III patients with colon cancer and importantly, in stage II patients, the Immunoscore® classification identified a subgroup of high-risk patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x